查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1465974

胚胎著床前基因檢測市場：按技術、產品、程序類型、應用、最終用戶 - 2024-2030 年全球預測

Preimplantation Genetic Testing Market by Technology, Offering, Procedure Type, Application, End User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年胚胎著床前基因檢測市場規模為7.284億美元，2024年將達8.2906億美元，2030年將達18.8628億美元，複合年成長率為14.56%。

胚胎著床前基因檢測（PGT）是指在胚胎著床前檢測影響胚胎的染色體異常的技術。 PGT是一項重要服務，能夠在體外受精（IVF）方法中及早發現胚胎著床前胚胎的遺傳異常，顯著降低將遺傳性疾病傳給後代的風險並提高成功率。 PGT 的主要應用領域包括識別單發疾病、染色體異常、粒線體疾病以及潛在兄弟姐妹的人類白血球抗原 (HLA) 匹配。由於生活方式的改變以及夫妻選擇生育的延遲導致不孕率不斷上升，因此需要開發PGT技術。政府促進體外受精治療的措施正在創造許多擴張機會。然而，與 IVF 治療和 PGT 程序相關的高成本可能是潛在最終用戶的主要阻礙力。圍繞 PGT 的倫理問題和 IVF 治療的有限保險範圍阻礙了 PGT 服務的採用。領先的生物技術公司正在迅速加強應對道德和監管挑戰，創造考慮道德和倫理因素的技術。次世代定序（NGS）和非侵入性胚胎著床前測試等新方法是新興技術，為該技術的發展提供了巨大潛力。

主要市場統計
基準年[2023] 7.284 億美元
預測年份 [2024] 82906萬美元
預測年份 [2030] 18.8628億美元
複合年成長率（%） 14.56%

檢測染色體異常和單基因疾病的下一代定序技術取得進展

比較基因組雜合反應(CGH) 已被用來比較兩個樣本的 DNA 來檢測染色體失衡。檢測胚胎著床前胚胎的染色體異常，有助於選擇健康胚胎進行體外受精。螢光原位雜合反應(FISH) 是一種使用螢光探針來視覺化和繪製細胞內染色體上特定 DNA 序列的技術。可以檢測染色體異常，包括非整倍體和易位。次世代定序(NGS) 能夠快速且準確地對大量 DNA序列測定，因此成為胚胎著床前基因檢測的強大工具。聚合酵素鏈鎖反應(PCR) 是一種廣泛使用的分子生物學技術，可擴增特定的 DNA 序列以進行分析和檢測單基因疾病。單核苷酸多態性（SNP）評估基因組中單核苷酸水平的變異，用於識別遺傳疾病的攜帶者並評估多因素疾病（包括癌症）的風險。

提供：利用多樣化的產品來最佳化製程條件並獲得準確的結果

該設備在 PGT 過程中發揮重要作用，因為它可以對胚胎進行準確、高效的基因篩檢。關鍵設備包括次世代定序儀(NGS)、定量 PCR (qPCR) 系統和螢光原位雜合反應(FISH) 分析儀。 NGS具有高通量定序能力和廣泛的檢測範圍，適合檢測單基因和染色體異常。 PGT使用的試劑和耗材由基因檢測所需的各種套件、探針、緩衝液、酵素、溶液等組成。探針對於檢測特定染色體異常至關重要，緩衝液為最佳擴增條件提供了適當的條件。軟體和服務是 PGT 不可或缺的一部分，因為它們可確保基因檢測結果的可靠資料管理、分析、解釋和報告。偏好圍繞著使用者友善的介面、準確的變異檢測演算法、用於變異註釋的綜合資料庫、安全的資料儲存選項等。

胚胎著床前遺傳學診斷（PGD）程序變得普及，降低了遺傳疾病的風險。

胚胎著床前遺傳學診斷（PGD）是一種專門的程序，可以在植入或懷孕前診斷出胚胎中的基因突變和染色體異常。 PGD​​ 的主要目的是降低某些遺傳疾病的風險，如囊腫纖維化、亨廷頓舞蹈症和肌肉萎縮症。胚胎著床前遺傳學篩檢（PGS），也稱為非整倍體染色體胚胎著床前遺傳學檢測（PGT-A），是在胚胎著床前胚胎中染色體非整倍性或不平衡的情況。透過識別具有正確染色體數量的胚胎，PGS旨在降低流產、死產、唐氏症和其他染色體異常的風險，並增加成功懷孕的機會。

廣泛使用胚胎著床前基因檢測來治療應用性非整倍體疾病

非整倍體是一種由於細胞內染色體數量異常而導致唐氏症、愛德華茲氏症候群和帕陶氏症等遺傳性疾病的疾病。胚胎著床前非整倍體基因檢測（PGT-A）可在胚胎著床前辨識出染色體異常的胚胎，進而增加成功懷孕的機會。透過胚胎著床前基因檢測進行性別鑑定，讓夫婦選擇孩子的性別，以平衡家庭並避免與性別相關的疾病。人類白血球抗原 (HLA) 分型可在幹細胞和器官移植過程中匹配供體和受體的組織類型。胚胎著床前HLA型檢測可以識別組織學相容的胚胎，並促進患有血液疾病或免疫系統缺陷的兄弟姐妹的成功植入。染色體結構異常涉及染色體結構的變化，包括缺失、重複和重排。此外，X連鎖疾病是由X染色體上的基因突變引起的，對男性的影響比女性更嚴重。

最終用戶：醫療研究機構擴大採用 PGT，以實現準確診斷和有效治療

胚胎著床前基因檢測廣泛應用於各種醫療機構，並在臨床研究中取得了成功。合約研究和製造組織 (CRMO) 是在產品開發、製造和商業化中發揮關鍵作用的關鍵組織。這些組織更喜歡外包服務，以確保品管、遵守監管標準和成本效率，同時專注於核心能力。同樣，冷凍庫是在極低的溫度下儲存精子、卵子和胚胎等生物樣本以供將來使用的機構。胚胎著床前基因檢測對於冷凍銀行至關重要，可確保在體外受精和顯微授精等移植程序之前儲存樣本的遺傳活力。醫院、診斷實驗室和服務供應商正在利用胚胎著床前基因檢測技術透過準確的診斷和有效的治療為患者護理做出貢獻。研究機構和學術機構透過尖端研究、技術開發和跨學科合作，在推動胚胎著床前基因檢測的創新和進步方面發揮關鍵作用。這些機構專注於開發下一代定序（NGS）等新技術，以提高胚胎著床前基因檢測方法的準確性。

區域洞察

在美洲，由於生活方式的改變和基因檢測意識的增強導致不孕率上升，因此對胚胎著床前基因檢測（PGT）的需求很高。改善的醫療基礎設施和優惠的報銷政策使美洲尋求不孕症治療的夫婦更容易獲得 PGT 服務。該地區企業擁有強大的研發能力，政府支持支持該領域的創新。亞洲是 PGT 的主要市場，因為 PGT 服務改善了 IVF 等先進生育技術的提供，擴大了醫療旅遊業，並吸引了尋求具有成本效益的治療選擇的外國患者。由於政府對醫療保健研究的資助增加以及 IVF 在歐洲國家普及等因素，歐洲對全球 PGT 市場做出了巨大貢獻。此外，圍繞基因檢測的嚴格法律規範確保了在進行 PGT 服務時的品管和道德考慮。該地區的主要企業正在為胚胎著床前基因檢測實踐的技術進步做出重大貢獻。

FPNV定位矩陣

FPNV定位矩陣對於評估胚胎著床前基因檢測市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對胚胎著床前基因測試市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

本報告在以下方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4. 競爭評估和情報：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況和製造能力進行全面評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1.胚胎著床前基因檢測市場規模及預測為何？

2.在胚胎著床前基因檢測市場的預測期間內，有哪些產品、細分市場、應用和領域需要考慮投資？

3.胚胎著床前基因檢測市場的技術趨勢和法規結構是什麼？

4.胚胎著床前基因檢測市場主要廠商的市場佔有率如何？

5. 進入胚胎著床前基因檢測市場的合適型態和策略性手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 胎兒畸形發生率高，需要健康、正常的胚胎移植
      • 全球不孕率上升和生育診所數量增加
      • 擴大早期診斷方法並增加政府對遺傳疾病治療的支持
    • 抑制因素
      • 與 PGT 相關的限制和風險
    • 機會
      • 胚胎著床前遺傳分析領域的技術進展
      • 胚胎著床前基因檢測領域的新興Start-Ups生態系與投資
    • 任務
      • PGT 的道德約束和濫用
  • 市場區隔分析
    • 技術：檢測染色體異常和單基因疾病的次世代定序取得進展
    • 我們提供什麼：利用各種服務來最佳化製程條件並獲得準確的結果。
    • 步驟：更多採用胚胎著床前遺傳學診斷 (PGD) 程序，以降低遺傳疾病的風險
    • 應用：胚胎著床前基因檢測廣泛用於非整倍體疾病
    • 最終用戶：醫療保健研究組織擴大採用 PGT，以實現準確診斷和有效治療
  • 市場趨勢分析
    • 在美洲部署創新的胚胎著床前遺傳解決方案的領先公司和新興企業
    • 政府的支持措施和不斷上升的不孕率強調了亞太地區採用胚胎著床前基因檢測。
    • 歐洲擴大採用體外受精胚胎著床前基因檢測，全球參與者可能在中東和非洲擴張
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法規結構分析

第6章胚胎著床前基因檢測市場：依技術分類

  • 比較基因組雜合反應
  • 螢光原位雜合技術
  • 次世代定序
  • 聚合酵素鏈鎖反應
  • 單核苷酸多態性

第7章胚胎著床前基因檢測市場：透過提供

  • 裝置
  • 試劑/耗材
  • 軟體和服務

第8章按程序類型分類的胚胎著床前基因檢測市場

  • 胚胎著床前遺傳學診斷
  • 胚胎著床前基因篩檢

第9章胚胎著床前基因檢測市場：依應用分類

  • 非整倍體
  • 性別認同
  • HLA型檢測
  • 單基因疾病
  • 染色體結構異常
  • X連鎖疾病

第 10 章胚胎著床前基因檢測市場：依最終用戶分類

  • 委託調查/製造組織
  • 冷凍庫
  • 醫院、診斷實驗室、服務供應商
  • 研究實驗室和學術機構

第11章美洲胚胎著床前基因檢測市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太胚胎著床前基因檢測市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲胚胎著床前基因檢測市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Thermo Fisher 推出 Ion ReproSeq PGT-A套件和 Ion AmpliSeq Ploidy套件
    • Kindbody推出Kindlabs 進行內部基因檢測
    • Medicover Genetics 和 FimLab Laboratories 宣布合作在芬蘭提供基因檢測服務
    • 美國 Fertility 和 Ovation 合併成為領先的 IVF 服務公司，改善生育治療服務的可近性
    • Eurofins Genoma 宣布推出 niPGT-A，一種非侵入性、免胚胎切片檢查的胚胎著床前遺傳非整倍體篩檢測試
    • GenEmbryomics 推出有史以來最全面的 IVF 基因檢測
    • 接受體外受精的新加坡人獲得某些類型治療的新資金
    • 澳洲 Fertilis 融資 200 萬美元用於自動化 IVF 胚胎培養

第15章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-030EE48515DA

[192 Pages Report] The Preimplantation Genetic Testing Market size was estimated at USD 728.40 million in 2023 and expected to reach USD 829.06 million in 2024, at a CAGR 14.56% to reach USD 1,886.28 million by 2030.

Preimplantation genetic testing (PGT) refers to technologies used to detect chromosomal abnormalities affecting the embryos before implantation. PGT is a crucial service that allows for early detection of genetic abnormalities in embryos before implantation during in-vitro fertilization (IVF) procedures, significantly reducing the risk of passing on inheritable diseases to offspring and improving IVF success rates. The primary application areas for PGT include identifying monogenic disorders, chromosomal abnormalities, mitochondrial diseases, and human leukocyte antigen (HLA) matching for potential siblings. The rising infertility rates due to lifestyle changes and delayed parenthood choices among couples have necessitated the development of PGT technologies. Government initiatives promoting IVF treatments create numerous expansion opportunities. However, high costs associated with IVF treatments and PGT procedures can be a major deterrent to potential end-users. Ethical concerns surrounding PGT and limited insurance coverage for IVF treatments hinder the adoption of PGT services. Major biotechnology companies are rapidly expanding efforts to combat ethical and regulatory challenges and creating technologies that take moral and ethical issues under consideration. New approaches such as next-generation sequencing (NGS) and non-invasive preimplantation testing are emerging technologies that offer significant potential for the growth of the technology.

KEY MARKET STATISTICS
Base Year [2023] USD 728.40 million
Estimated Year [2024] USD 829.06 million
Forecast Year [2030] USD 1,886.28 million
CAGR (%) 14.56%

Technology: Advancements in next-generation sequencing to detect chromosomal abnormalities and single-gene disorders

Comparative genomic hybridization (CGH) is adopted for detecting chromosomal imbalances by comparing the DNA of two samples. It can detect chromosomal abnormalities in embryos before implantation and help select healthy embryos for IVF. Fluorescence in situ hybridization (FISH) is a technique that uses fluorescent probes to visualize and map specific DNA sequences on chromosomes within cells. It can detect numerical chromosomal abnormalities, including aneuploidy or translocations. Next-generation sequencing (NGS) is a robust tool for preimplantation genetic testing owing to its ability to sequence large amounts of DNA quickly and accurately. Polymerase chain reaction (PCR) is a widely used molecular biology technique that amplifies specific DNA sequences for analysis and can detect monogenic diseases. Single-nucleotide polymorphism (SNP) evaluates variations at the single-nucleotide level within the genome and is used to identify carriers of inherited diseases or assess the risk of multifactorial disorders, including cancer.

Offering: Utilization of diverse offerings to optimize process conditions and derive accurate results

Instruments play a critical role in the PGT process as they enable accurate and efficient genetic screening of embryos. Key instruments include next-generation sequencers (NGS), quantitative PCR (qPCR) systems, and fluorescence in situ hybridization (FISH) analyzers. NGS offers high-throughput sequencing capabilities and a broader detection range, making it suitable for detecting single-gene disorders and chromosomal abnormalities. Reagents and consumables used for PGT consist of various kits, probes, buffers, enzymes, and solutions necessary for genetic testing procedures. Probes are vital in detecting specific chromosomal aberrations, and buffers provide appropriate conditions for optimal amplification conditions. Software and services are essential components of PGT, as they ensure reliable data management, analysis, interpretation, and reporting for genetic testing results. Need-based preferences revolve around user-friendly interfaces, accurate algorithms for variant detection, comprehensive databases for variant annotation, and secure data storage options.

Procedure: Increasing deployment of preimplantation genetic diagnosis (PGD) procedures to reduce the risk of genetic disorders

Preimplantation genetic diagnosis (PGD) is a specialized procedure that allows the identification of genetic mutations or chromosomal abnormalities in embryos diagnosed before implantation and pregnancy. The primary goal of PGD is to reduce the risk of developing specific genetic disorders such as cystic fibrosis, Huntington's disease, and muscular dystrophy. Preimplantation genetic screening (PGS), referred to as preimplantation genetic testing for aneuploidies (PGT-A), detects chromosomal aneuploidies or imbalances in embryos before implantation. PGS aims to improve the chances of successful pregnancies by identifying embryos with the correct number of chromosomes, reducing the risk of miscarriage, stillbirth, or having a child affected by Down syndrome or other chromosomal abnormalities.

Application: Wide use of preimplantation genetic testing for aneuploidy disorder

Aneuploidy is a disorder in which an abnormal number of chromosomes in a cell leads to genetic disorders, including Down syndrome, Edwards syndrome, and Patau syndrome. Preimplantation of genetic testing for aneuploidy (PGT-A) identifies embryos with chromosomal abnormalities before implantation, increasing the chances of a successful pregnancy outcome. Gender identification through preimplantation genetic testing allows couples to choose the gender of their child for family balancing or to avoid sex-linked disorders. Human leukocyte antigen (HLA) typing matches tissue types between donor and recipient for stem cell or organ transplantation procedures. Preimplantation HLA typing identifies embryos with compatible tissue types, potentially facilitating successful transplants in siblings with blood disorders or immune system deficiencies. Structural chromosomal abnormalities involve alterations in chromosome structure, including deletions, duplications, and rearrangements. In addition, X-linked diseases are caused by mutations in genes on the X chromosome, affecting males more severely than females.

End User: Increasing adoption of PGT in healthcare research organizations for accurate diagnosis and effective treatments

Preimplantation genetics testing is widely used in various healthcare facilities, providing successful outcomes in clinical research. Contract research and manufacturing organizations (CRMOs) are primary organizations that play a crucial role in developing, manufacturing, and commercializing preimplantation genetic testing products. These organizations prefer outsourcing their services to ensure quality control, compliance with regulatory standards, and cost efficiency while focusing on their core competencies. Similarly, cryobanks are institutions that store biological samples such as sperm, eggs, and embryos at extremely low temperatures for future use. Preimplantation genetic testing is crucial for cryobanks to ensure the genetic viability of stored samples before implantation procedures like IVF or ICSI. Hospitals, diagnostic labs, and service providers contribute to patient care through accurate diagnosis and effective treatments using preimplantation genetic testing technologies. Research laboratories and academic institutes play a vital role in driving innovation and advancements in preimplantation genetic testing through cutting-edge research, technological developments, and interdisciplinary collaborations. These institutions focus on developing novel techniques like next-generation sequencing (NGS) to enhance the accuracy of preimplantation genetic testing methods.

Regional Insights

The Americas exhibit a high need for preimplantation genetic testing (PGT) owing to rising infertility rates caused by lifestyle changes and increasing awareness regarding genetic testing. Well-established healthcare infrastructure facilities and favorable reimbursement policies have made PGT services more accessible to couples seeking infertility treatments in the Americas. Companies in the region have strong R&D capabilities and government support that drive innovation in the field. Asia is emerging as a big and opportunistic market for PGT owing to improved provision of advanced fertility techniques such as IVF with PGT services and growing medical tourism, attracting international patients seeking cost-effective treatment options. Europe contributes significantly to the global PGT market due to factors such as increased government funding for healthcare research and widespread adoption of IVF procedures across various European countries. Moreover, stringent regulatory frameworks surrounding genetic testing ensure quality control and ethical considerations when implementing PGT services. Key players within this region contribute significantly to technological advancements in preimplantation genetic testing practices.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Preimplantation Genetic Testing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Preimplantation Genetic Testing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Preimplantation Genetic Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Bioarray S.L., EUROPE IVF International s.r.o., F. Hoffmann-La Roche AG, Genea Limited, GENETiKS, Illumina, Inc., Invicta Genetics, Invitae Corporation, Juno Genetics, US Inc., Laboratory Corporation of America Holdings, MedGenome Labs Ltd., Merck KGaA, Natera, Inc., NextGen Genetics Holdings, LLC, Ovation Fertility, PacGenomics, PerkinElmer, Inc., Progyny, Inc., Qiagen N.V., Quest Diagnostics Incorporated, Reproductive Genetic Innovations, LLC, SEQUENCE46, LLC, Sysmex Corporation, Takara Bio Inc., The Cooper Companies Inc., Thermo Fisher Scientific Inc., Vitrolife Sweden AB, and Yikon Genomics (Shanghai) Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Preimplantation Genetic Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Technology
    • Comparative Genomic Hybridization
    • Fluorescence in-Situ Hybridization
    • Next-Generation Sequencing
    • Polymerase Chain Reaction
    • Single-Nucleotide Polymorphism
  • Offering
    • Instruments
    • Reagents & Consumables
    • Software & Services
  • Procedure Type
    • Preimplantation Genetic Diagnosis
    • Preimplantation Genetic Screening
  • Application
    • Aneuploidy
    • Gender Identification
    • HLA Typing
    • Single Gene Disorders
    • Structural Chromosomal Abnormalities
      • Deletions
      • Duplications
      • Inversions
      • Translocations
    • X-Linked Disorders
  • End User
    • Contract Research & Manufacturing Organizations
    • Cryobanks
    • Hospitals, Diagnostic Labs, & Service Providers
    • Research Laboratories & Academic Institutes
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Preimplantation Genetic Testing Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Preimplantation Genetic Testing Market?

3. What are the technology trends and regulatory frameworks in the Preimplantation Genetic Testing Market?

4. What is the market share of the leading vendors in the Preimplantation Genetic Testing Market?

5. Which modes and strategic moves are suitable for entering the Preimplantation Genetic Testing Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Significant incidences of fetal abnormalities and need for healthy and successful embryo implantation
      • 5.1.1.2. Increase in the rate of infertility and the rising number of fertility clinics worldwide
      • 5.1.1.3. Growing early diagnostic approaches coupled with increasing government support to treat genetic diseases
    • 5.1.2. Restraints
      • 5.1.2.1. Limitation and risks associated with PGT
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancement in the field of preimplantation genetic analysis
      • 5.1.3.2. Emerging startup ecosystem and investments in the field of preimplantation genetic testing
    • 5.1.4. Challenges
      • 5.1.4.1. Ethical constraints and Misuse of PGT
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Technology: Advancements in next-generation sequencing to detect chromosomal abnormalities and single-gene disorders
    • 5.2.2. Offering: Utilization of diverse offerings to optimize process conditions and derive accurate results
    • 5.2.3. Procedure: Increasing deployment of preimplantation genetic diagnosis (PGD) procedures to reduce the risk of genetic disorders
    • 5.2.4. Application: Wide use of preimplantation genetic testing for aneuploidy disorder
    • 5.2.5. End User: Increasing adoption of PGT in healthcare research organizations for accurate diagnosis and effective treatments
  • 5.3. Market Trend Analysis
    • 5.3.1. Presence of established companies and startups launching innovative preimplantation genetic solutions across the Americas
    • 5.3.2. Supportive Government initiatives and the increasing infertility rate emphasized preimplantation genetic testing adoption in APAC
    • 5.3.3. Rising adoption of preimplantation genetic testing for IVF across Europe and potential of global player expansion in Middle East & Africa
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework Analysis

6. Preimplantation Genetic Testing Market, by Technology

  • 6.1. Introduction
  • 6.2. Comparative Genomic Hybridization
  • 6.3. Fluorescence in-Situ Hybridization
  • 6.4. Next-Generation Sequencing
  • 6.5. Polymerase Chain Reaction
  • 6.6. Single-Nucleotide Polymorphism

7. Preimplantation Genetic Testing Market, by Offering

  • 7.1. Introduction
  • 7.2. Instruments
  • 7.3. Reagents & Consumables
  • 7.4. Software & Services

8. Preimplantation Genetic Testing Market, by Procedure Type

  • 8.1. Introduction
  • 8.2. Preimplantation Genetic Diagnosis
  • 8.3. Preimplantation Genetic Screening

9. Preimplantation Genetic Testing Market, by Application

  • 9.1. Introduction
  • 9.2. Aneuploidy
  • 9.3. Gender Identification
  • 9.4. HLA Typing
  • 9.5. Single Gene Disorders
  • 9.6. Structural Chromosomal Abnormalities
  • 9.7. X-Linked Disorders

10. Preimplantation Genetic Testing Market, by End User

  • 10.1. Introduction
  • 10.2. Contract Research & Manufacturing Organizations
  • 10.3. Cryobanks
  • 10.4. Hospitals, Diagnostic Labs, & Service Providers
  • 10.5. Research Laboratories & Academic Institutes

11. Americas Preimplantation Genetic Testing Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Preimplantation Genetic Testing Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Preimplantation Genetic Testing Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Thermo Fisher Unveils Ion ReproSeq PGT-A Kit and Ion AmpliSeq Polyploidy Kit
    • 14.3.2. Kindbody Brings Genetic Testing In-House with the Launch of Kindlabs
    • 14.3.3. Medicover Genetics and Fimlab Laboratories Announce Partnership to Provide Genetic Testing Services in Finland
    • 14.3.4. U.S. Fertility and Ovation Combine to Create IVF Services Powerhouse, Increasing Access to Fertility Services
    • 14.3.5. Eurofins Genoma Announces Launch of niPGT-A, a Non-Invasive, Embryo Biopsy Free, Preimplantation Genetic Aneuploidy Screening
    • 14.3.6. GenEmbryomics Introduces the Most Complete IVF Genetic Test Ever Made Available
    • 14.3.7. Singaporeans Undergoing IVF to Get New Funding For Some Types of Preimplantation Genetic Testing
    • 14.3.8. Australia's Fertilis Raised USD 2 Million to Automate IVF Embryo Culturing

15. Competitive Portfolio

  • 15.1. Key Company Profiles
  • 15.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. PREIMPLANTATION GENETIC TESTING MARKET RESEARCH PROCESS
  • FIGURE 2. PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. PREIMPLANTATION GENETIC TESTING MARKET DYNAMICS
  • FIGURE 7. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 16. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 20. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 25. PREIMPLANTATION GENETIC TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 26. PREIMPLANTATION GENETIC TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PREIMPLANTATION GENETIC TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY FLUORESCENCE IN-SITU HYBRIDIZATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY FLUORESCENCE IN-SITU HYBRIDIZATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SINGLE-NUCLEOTIDE POLYMORPHISM, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SINGLE-NUCLEOTIDE POLYMORPHISM, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PREIMPLANTATION GENETIC DIAGNOSIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PREIMPLANTATION GENETIC DIAGNOSIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PREIMPLANTATION GENETIC SCREENING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PREIMPLANTATION GENETIC SCREENING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY ANEUPLOIDY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY ANEUPLOIDY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY GENDER IDENTIFICATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY GENDER IDENTIFICATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY HLA TYPING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY HLA TYPING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SINGLE GENE DISORDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SINGLE GENE DISORDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY DELETIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY DELETIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY DUPLICATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY DUPLICATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY INVERSIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY INVERSIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TRANSLOCATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TRANSLOCATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY X-LINKED DISORDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY X-LINKED DISORDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 57. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 58. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 59. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY CONTRACT RESEARCH & MANUFACTURING ORGANIZATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 60. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY CONTRACT RESEARCH & MANUFACTURING ORGANIZATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 61. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY CRYOBANKS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 62. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY CRYOBANKS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 63. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY HOSPITALS, DIAGNOSTIC LABS, & SERVICE PROVIDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 64. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY HOSPITALS, DIAGNOSTIC LABS, & SERVICE PROVIDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 65. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 66. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 67. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 68. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 69. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 70. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 71. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 72. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 73. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 74. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 75. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2023 (USD MILLION)
  • TABLE 76. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2024-2030 (USD MILLION)
  • TABLE 77. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 78. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 79. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 80. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 81. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 82. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 83. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 84. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 85. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 86. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 87. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 88. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 89. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2023 (USD MILLION)
  • TABLE 90. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2024-2030 (USD MILLION)
  • TABLE 91. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 92. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 93. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 94. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 95. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 96. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 97. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 98. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 99. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 100. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 101. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2023 (USD MILLION)
  • TABLE 102. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2024-2030 (USD MILLION)
  • TABLE 103. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 104. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 105. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 106. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 107. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 108. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 109. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 110. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 111. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 112. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 113. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2023 (USD MILLION)
  • TABLE 114. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2024-2030 (USD MILLION)
  • TABLE 115. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 116. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 117. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 118. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 119. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 120. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 121. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 122. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 123. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 124. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 125. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2023 (USD MILLION)
  • TABLE 126. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2024-2030 (USD MILLION)
  • TABLE 127. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 128. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 129. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 130. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 131. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 132. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 133. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 134. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 135. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 136. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 137. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2023 (USD MILLION)
  • TABLE 138. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2024-2030 (USD MILLION)
  • TABLE 139. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 140. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 141. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 142. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2023 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2024-2030 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 157. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 158. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 159. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 160. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 161. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 162. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 163. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 164. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 165. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2023 (USD MILLION)
  • TABLE 166. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2024-2030 (USD MILLION)
  • TABLE 167. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 168. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 169. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 170. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 171. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 172. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 173. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 174. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 175. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 176. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 177. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2023 (USD MILLION)
  • TABLE 178. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2024-2030 (USD MILLION)
  • TABLE 179. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 180. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 181. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 182. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 183. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 184. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 185. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 186. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 187. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 188. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 189. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2023 (USD MILLION)
  • TABLE 190. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2024-2030 (USD MILLION)
  • TABLE 191. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 192. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 193. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 194. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 195. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 196. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 197. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 198. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 199. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 200. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 201. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2023 (USD MILLION)
  • TABLE 202. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2024-2030 (USD MILLION)
  • TABLE 203. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 204. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 205. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 206. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 207. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 208. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 209. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 210. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 211. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 212. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 213. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2023 (USD MILLION)
  • TABLE 214. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2024-2030 (USD MILLION)
  • TABLE 215. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 216. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 217. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 218. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 219. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 220. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 221. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 222. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 223. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 224. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 225. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2023 (USD MILLION)
  • TABLE 226. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2024-2030 (USD MILLION)
  • TABLE 227. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 228. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 229. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 230. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 231. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 232. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 233. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 234. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 235. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 236. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 237. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2023 (USD MILLION)
  • TABLE 238. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2024-2030 (USD MILLION)
  • TABLE 239. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 240. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 241. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 242. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 243. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 244. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 245. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 246. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 247. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 248. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 249. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2023 (USD MILLION)
  • TABLE 250. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2024-2030 (USD MILLION)
  • TABLE 251. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 252. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 253. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 254. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 255. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 256. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 257. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 258. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 259. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 260. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 261. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2023 (USD MILLION)
  • TABLE 262. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2024-2030 (USD MILLION)
  • TABLE 263. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 264. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 265. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 266. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 267. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 268. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 269. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 270. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 271. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 272. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 273. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2023 (USD MILLION)
  • TABLE 274. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2024-2030 (USD MILLION)
  • TABLE 275. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 276. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 277. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 278. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 279. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 280. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 281. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 282. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 283. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 284. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 285. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2023 (USD MILLION)
  • TABLE 286. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2024-2030 (USD MILLION)
  • TABLE 287. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 288. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 289. VIETNAM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 290. VIETNAM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 291. VIETNAM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 292. VIETNAM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 293. VIETNAM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 294. VIETNAM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 295. VIETNAM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 296. VIETNAM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 297. VIETNAM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNO